Olema Pharmaceuticals (OLMA) Research & Development (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Research & Development data on file, last reported at $49.2 million in Q1 2026.

• Research & Development for Q1 2026 came in at $49.2 million, up 60.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $176.3 million (up 40.75% YoY), and the FY2025 annual result was $157.7 million, up 26.65% from the prior year.
• Research & Development rose to $49.2 million in Q1 2026 per OLMA's latest filing, from $43.2 million in the prior quarter.
• Over five years, Research & Development peaked at $49.2 million in Q1 2026 and troughed at $16.0 million in Q1 2022.
• A 5-year average of $29.4 million and a median of $29.1 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2023: Research & Development soared 127.15% in 2022, then plunged 33.51% in 2023.
• A 5-year view of Research & Development shows it stood at $21.6 million in 2022, then advanced by 19.87% to $25.9 million in 2023, then rose by 24.84% to $32.3 million in 2024, then jumped by 33.81% to $43.2 million in 2025, then grew by 13.91% to $49.2 million in 2026.
• Business Quant data shows OLMA's Research & Development at $49.2 million in Q1 2026, $43.2 million in Q4 2025, and $40.0 million in Q3 2025.